Market research
STIM Neuronetics Inc
NASDAQ USD Healthcare
Latest close
As of 30 Oct 2026
Test a moving-average rule with historical data.
Market facts
- Market cap
- 144M
- P/E ratio
- Not available
- Analyst target
- 5.75
- Dividend yield
- Not available
- Beta
- 1.2
Profile
Instrument facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Medical Devices
- ISIN
- Not available
- Market cap
- 144M
- P/E ratio
- Not available
- Analyst target
- 5.75
- Dividend yield
- Not available
- Beta
- 1.2
About
About Neuronetics Inc
Neuronetics, Inc. engages in providing in office treatments for patients with neurohealth disorders in the United States and internationally. The company provides NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder. Its NeuroStar Advanced Therapy System uses transcranial magnetic stimulation to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The company sells its products through its sales and customer support team to psychiatrists. Neuronetics, Inc. has a strategic collaboration with ANT Neuro to expand the capabilities of the NeuroStar advanced therapy system with advanced image-guided navigation technology. The company was incorporated in 2001 and is headquartered in Malvern, Pennsylvania.
Research context
Neuronetics Inc appears in PyInvesting’s US Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- USD
- Sector
- Healthcare
- Industry
- Medical Devices
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
Community
Investor discussion
1 comment
Sign in to join the STIM discussion.
5 years, 6 months ago
Neuronetics, Inc is currently in a long term uptrend where the price is trading 18.5% above its 200 day moving average.
From a valuation standpoint, the stock is 99.6% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 4.7.
Neuronetics, Inc's total revenue sank by 10.2% to $16M since the same quarter in the previous year.
Its net income has increased by 51.6% to $-4M since the same quarter in the previous year.
Finally, its free cash flow grew by 73.1% to $-2M since the same quarter in the previous year.
Based on the above factors, Neuronetics, Inc gets an overall score of 4/5.